Substance
ID:474
Names and Identifiers
IUPAC Traditional name
synalar
Synonyms
Fluocinolone AcetonideFluocinolonacetonidumflucinoloneFluocinolone acetonide [DCIT]Fluocinoloni acetonidum [INN-Latin]
Brand Name
FlupollonLocalyn SyntexOmnidermSynamolSynandroneSynoticSynsacTefunoteFluonidJellinNeo-SynalarRadiocinRetisertSynandoneSynalarSynalar-HPSynemolDerma-smoothe/fsDermalarFlucinarFlucortFS ShampooLocalynSinalarCoriphateFluocetFluotrexFluovitifPercutinaMedidur
IUPAC name
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
Properties
Physical Property
Hydrophobicity(logP)
2.48 [HANSCH,C ET AL. (1995)]
Molecule Details
Drug Groups
approved; investigational
Description
A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). It is also being investigatied by pSivida and Alimera, under the brand name Medidur, as a sustained release intraocular implant for the treatment of diabetic macular edema.
Indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert).
Affected Organisms
Humans and other mammals
Biotransformation
Primarily hepatic, corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Absorption
Rapidly absorbed (15 minutes)
Half Life
1.3-1.7 hours
Elimination
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
References
•
Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, Usner DW, Comstock TL: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007 Nov;125(11):1478-85. Epub 2007 Oct 8.
[Pubmed]
•
Brumm MV, Nguyen QD: Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64.
[Pubmed]
•
Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, Usner DW, Comstock TL: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007 Nov;125(11):1478-85. Epub 2007 Oct 8. Pubmed
• Brumm MV, Nguyen QD: Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64. Pubmed
• Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75. Pubmed